Biotica, Pfizer deal

Biotica said Pfizer terminated a 2006 deal and returned full rights to the rapamycin analog program. Biotica said Pfizer made the decision as part of a portfolio review process. Biotica will continue development of undisclosed candidates in multiple sclerosis (MS) and systemic lupus erythematosus (SLE), which were evaluated by Pfizer. Biotica said the lead compound is slated to begin Phase I trials in 6-12 months. Details were not disclosed (see BioCentury, Oct. 9, 2006). ...